- 全部删除
您的购物车当前为空
BAY1082439 是一种具有口服活性的,选择性 PI3Kα/β/δ抑制剂。它也能抑制 PIK3CA 的突变形式,它对抑制 Pten 丢失的前列腺癌的生长有很强的作用。


为众多的药物研发团队赋能,
让新药发现更简单!
BAY1082439 是一种具有口服活性的,选择性 PI3Kα/β/δ抑制剂。它也能抑制 PIK3CA 的突变形式,它对抑制 Pten 丢失的前列腺癌的生长有很强的作用。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 315 | 待询 | |
| 2 mg | ¥ 453 | 待询 | |
| 5 mg | ¥ 728 | 待询 | |
| 10 mg | ¥ 1,230 | 待询 | |
| 25 mg | ¥ 1,980 | 待询 | |
| 50 mg | ¥ 3,730 | 待询 | |
| 100 mg | ¥ 5,380 | 待询 |
BAY1082439 相关产品
| 产品描述 | BAY1082439, an orally bioavailable, selective inhibitor of PI3Kα/β/δ, demonstrates high efficacy in inhibiting the growth of Pten-null prostate cancer [1][2]. Additionally, BAY1082439 is effective against mutated forms of PIK3CA. |
| 体外活性 | BAY1082439 is a highly selective PI3Kα/α-balanced inhibitor. BAY1082439 (0.1-1 μM; 72 hours) is more effective than PI3Kα- and/or PI3Kβ-selective inhibitors in blocking PTEN-null prostate cancer cells[2]. BAY1082439 has an IC50 ratio of 1:3 in biochemical assays of PI3Kα (4.9 nM) vs. PI3Kα (15.0 nM), and >1000-fold selectivity against mTOR kinase[1]. |
| 体内活性 | BAY1082439 (75 mg/kg; p.o.; daily for 4 weeks) is effective in preventing Pten-null prostate cancer progression[2]. |
| 别名 | N-[8-[[(2R)-2-羟基-3-(吗啉-4-基)丙基]氧基]-7-甲氧基-2,3-二氢咪唑并[1,2-C]喹唑啉-5-基]-2-甲基吡啶-3-甲酰胺 |
| 分子量 | 494.54 |
| 分子式 | C25H30N6O5 |
| CAS No. | 1375469-38-7 |
| Smiles | COc1c(OC[C@H](O)CN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cccnc3C)=Nc12 |
| 密度 | 1.43 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度信息 | DMSO: Slightly soluble |
评论内容